Legend Biotech
Legend Biotech Corp is a global clinical-stage biopharmaceutical company developing cell therapies for oncology and hematologic malignancies. The company focuses on discovering and developing chimeric antigen receptor T-cell therapies, featuring its lead commercial product Carvykti for relapsed or refractory multiple myeloma. Principal revenues are generated through commercial sales of its cell therapy, collaborative development milestones, and licensing agreements with Janssen Biotech. Core end markets encompass specialized oncology medical centers, hematology treatment clinics, and academic research hospitals worldwide. Legend Biotech holds a pioneering market position in CAR-T cell therapy for hematologic cancers. The company is incorporated in the Cayman Islands, headquartered in Somerset, New Jersey, and its American Depositary Shares trade on the Nasdaq Global Select Market.
11 of the funds FundTelligence covers report a position in Legend Biotech.
- Legal name
- Legend Biotech Corp
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 11
Funds holding Legend Biotech
- JPM Global Healthcare Fund — JPM · 0.44 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.14 % (full portfolio disclosed, October 2026)
- KLP AksjeFremvoksende Markeder Indeks — KLP · 0.04 % (full portfolio disclosed, June 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.03 % (full portfolio disclosed, October 2026)
- Storebrand Emerging Markets — Storebrand · 0.02 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.01 % (full portfolio disclosed, October 2026)
- Mercer Passive Emerging Markets Equity Fund — Mercer · 0.01 % (full portfolio disclosed, December 2025)
- Storebrand Indeks Nye Markeder — Storebrand · 0.01 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 11 funds holding it.